These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11564066)

  • 21. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?
    Cohen Y; Da'as N; Libster D; Amir G; Berrebi A; Polliack A
    Eur J Haematol; 2002 Feb; 68(2):80-3. PubMed ID: 12038452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in chronic lymphocytic leukemia.
    Montserrat E
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):34-9. PubMed ID: 12652463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
    Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
    Lenz G; Hiddemann W; Dreyling M
    Cancer; 2004 Sep; 101(5):883-93. PubMed ID: 15329894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
    Byrd JC; Kitada S; Flinn IW; Aron JL; Pearson M; Lucas D; Reed JC
    Blood; 2002 Feb; 99(3):1038-43. PubMed ID: 11807010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Fludarabine for the Treatment of Indolent Lymphoma with Chylothorax.
    Wild A; Holasová J; Králiková E
    Klin Onkol; 2018; 31(4):301-304. PubMed ID: 30541315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
    Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine: a review of its use in non-Hodgkin's lymphoma.
    Anderson VR; Perry CM
    Drugs; 2007; 67(11):1633-55. PubMed ID: 17661532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
    Polito L; Bolognesi A; Tazzari PL; Farini V; Lubelli C; Zinzani PL; Ricci F; Stirpe F
    Leukemia; 2004 Jul; 18(7):1215-22. PubMed ID: 15103391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
    Tsutsumi Y; Kanamori H; Minami H; Musashi M; Fukushima A; Ehira N; Yamato H; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2005 Apr; 84(4):269-71. PubMed ID: 15592832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
    Pathan NI; Chu P; Hariharan K; Cheney C; Molina A; Byrd J
    Blood; 2008 Feb; 111(3):1594-602. PubMed ID: 18032710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
    Brien G; Trescol-Biemont MC; Bonnefoy-Bérard N
    Oncogene; 2007 Aug; 26(39):5828-32. PubMed ID: 17353899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
    Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
    Savage DG; Cohen NS; Hesdorffer CS; Heitjan D; Oster MW; Garrett TJ; Bar M; del Prete S; March R; Lonberg M; Talbot S; Mears JG; Flamm M; Taub RN; Nichols G
    Leuk Lymphoma; 2003 Mar; 44(3):477-81. PubMed ID: 12688318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
    Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
    Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
    Lepretre S; Jäger U; Janssens A; Leblond V; Nikitin E; Robak T; Wendtner CM
    Leuk Lymphoma; 2012 May; 53(5):820-9. PubMed ID: 21992675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
    Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
    Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.